REVIEW: A NOVEL DRUG FIRIBASTAT IS FIRST-IN-CLASS BRAIN AMINOPEPTIDASE A INHIBITOR TREATMENT ON HYPERTENSION

• Author(s):

  Ajay Bhojane | Dipak Ghodekar | Vikas Kandekar | Narendra Gowekar

• Keywords:

  Hypertension, Aminopeptidase, Stimulation, Quantum Genomics

• Abstract:

  Firibastat Is The New First-in-class Centrally Acting Aminopeptidase A Inhibitor Prodrug. Pharmacologically, Firibastat Prevents The Conversion Of Angiotensin-II To Angiotensin-III, One Of The Main Effector Peptides Of The Brain Renin–angiotensin System

---

Other Details

• Paper id:

  IJSARTV8I654930

• Published in:

  Volume: 8 Issue: 6 June 2022

• Publication Date:

  2022-06-02

Download Article